1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833. [PubMed] 2. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) Blood. 2006;108:4003–4008. [PubMed] 3. Ghielmini M, Schmitz SFH, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule. Blood. 2004;103:4416–4423. [PubMed] 4. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005;23:1096–1102. [PubMed] 5. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127. [PubMed]
6. Hagenbeek A, Van Glabbeke M, Teodorovic I. The role of rituximab maintenance treatment in relapsed folicular NHL an interim analysis of the EORTC randomized intergroup trial. Ann Oncol. 2005;16:61.
7. Hainsworth JD, Litchy S, Burris HA, Scullin DC, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–4267. [PubMed]
8. Hochster HS, Weller EA, Gascoyne RD, Ryan TS, Habermann TM, Gordon LI, et al. Rituximab after CVP results in superior clinical outcome in advanced folicular lymphoma (FL): results of the E1496 Phase III Trial from the eastern Cooperative Oncology Group and Cancer Leukemia Group B. Blood. 2005;106:349.
9. van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–3301. [PubMed] 10. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–3143. [PubMed]
11. Genentech Inc., and Biogen Idec. Rituxan, authors. Prescribing information. 2008.
12. Manshouri T, Do KA, Wang XM, Giles FJ, O’Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513. [PubMed] 13. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies-historical and future perspectives. Haematologica. 2009 [PubMed] 14. Selenko N, Majdic O, Draxler S, Berer A, Jager U, Knapp W, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8(+) cytotoxic T cells. Leukemia. 2001;15:1619–1626. [PubMed] 15. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–1652. [PubMed] 16. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas N, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038–1043. [PubMed] 17. Stolz C, Hess G, Hahnel PS, Grabellus F, Hoffarth S, Schmid KW, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008;112:3312–3321. [PubMed] 18. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–3837. [PubMed] 19. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443–446. [PubMed] 20. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene. Blood. 2002;99:754–758. [PubMed]
21. Treon SP, Fox EA, Hansen M, Verselis S, Branagan A, Touroutoglou N, et al. Polymorphisms in Fc gamma RIIIa (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macro-globulinemia. Blood. 2002;100:573.
22. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clinl Oncol. 2003;21:3940–3947. [PubMed] 23. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for Linkage Disequilibrium Between Fc gamma RIIIa-V158F and Fc gamma RIIa-H131R Polymorphisms in White Patients, and for an Fc gamma RIIIa-Restricted Influence on the Response to Therapeutic Antibodies. J Clin Oncol. 2008;26:5489–5491. [PubMed] 24. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc-gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004;103:1472–1474. [PubMed] 25. Gong Q, Ou QL, Ye SM, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817–826. [PubMed] 26. Uchida JJ, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659–1669. [PMC free article] [PubMed] 27. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc gamma RI, Fc gamma RIII and Fc gamma RIV. Blood. 2008;112:1205–1213. [PubMed] 28. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin in Immunol. 2007;19:239–245. [PubMed] 29. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204:55–63. [PubMed] 30. Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045–1052. [PubMed] 31. Golay J, Zaffaroni L, Vaccari T, Borleri GM, Tedesco F, Dastoli G, et al. Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis. Blood. 1999;94:92. [PubMed] 32. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B-Cells In-Vivo by A Chimeric Mouse-Human Monoclonal-Antibody to CD20. Blood. 1994;83:435–445. [PubMed] 33. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–2743. [PubMed] 34. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematol-the Hematol J. 2006;91:176–183. [PubMed] 35. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280–3288. [PubMed] 36. Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 2007;8:361–362. [PubMed] 37. Beers SA, Chan CHT, James S, French RR, Attfield KE, Brennan CM, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112:4170–4177. [PubMed] 38. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98:1352–1357. [PubMed] 39. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176:2600–2609. [PubMed] 40. Li YL, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007;179:4263–4271. [PubMed] 41. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006;177:7435–7443. [PubMed] 42. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, et al. A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. Clin Can Res. 2008;14:6697–6703. [PMC free article] [PubMed] 43. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800. [PubMed]
44. Hagenbeek A, Plesner T, Johnson P, Pedersen L, Walewski J, Hellmann A, et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins’s lymphoma. Blood. 2005;106:270.
45. Coiffier B, Tilly H, Pederson LM, Plesner T, Frederiksen H, van Oears MHJ, et al. HuMax-CD20, a novel human monoclonal antibody in chronic lymphocytic leukemia:early results from an ongoingPhase I/II clinical trial. Blood. 2005;106:448.
46. Du JM, Yang H, Guo YJ, Ding JP. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009;46:2419–2423. [PubMed] 47. Du JM, Wang H, Zhong C, Peng BZ, Zhang ML, Li BH, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem. 2007;282:15073–15080. [PubMed] 48. Taylor RP, Pawhiczkowycz AW, Lindorfer MA, de Winkel JGJV, Beurskens FJ, Parren PWHI. Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX. Blood. 2008;112:560. [PubMed] 49. Du JM, Wang H, Zhong C, Peng BZ, Zhang ML, Li BH, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol. 2008;45:2861–2868. [PubMed] 50. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis-A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652–2661. [PubMed] 51. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Dr. 2008;9:1206–1215. [PubMed]
52. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, et al. Activity of veltuzumab, a second-generation humanized anti-CD20 mAb, in laboratory and clinical studies. Ann Oncol. 2008;19:130.
53. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113:1062–1070. [PubMed] 54. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, et al. Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin’s Lymphoma: Phase I/II Results. J Clin Oncol. 2009;27:3346–3353. [PubMed] 55. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009;11:200–207. [PubMed] 56. Barone D, Burge DJ, Baum P, Ledbetter J, Hayden-Ledbetter M, Mohler K. Prolonged depletion of circulating B cells in cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic. Ann Rheum Dis. 2005;64:159–160. [PubMed]
57. Barone D, Nilsson C, Ledbetter J, Hayden-Ledbetter M, Mohler K. TRU-015, a novel CD20-directed biologic therapy, demonstrates significant anti-tumor activity in human tumor xenograft models. J Clin Oncol. 2005;23:178.
58. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, et al. CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells. Clin Can Res. 2009;15:2739–2746. [PubMed] 59. Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J, et al. Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP (TM)) protein therapeutic, in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007;9 [PubMed]
60. Burge DJ, Shu C, Martin RW, Littlejohn TW, Wallace DJ, Taborn J, et al. TRU-015, a small modular immunopharmaceutical (SMIP (TM)) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007;9
61. Burge D, Chopiak V, Dvoretskiy L, Koshukova G, Nasonov E, Povoroznyuk V, et al. TRU-015 improves rheumatoid arthritis disease activity in a randomized, double-blind, placebo-controlled, multi-center phase 2 dose ranging trial. Arthritis Rheum. 2007;56:4234–4235.
62. Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J, et al. Phase 1 study of TRU-015, a CD20 directed small modular immunopharmaceutical (SMIP TM) protein therapeutic, in subjects with rheumatoid arthritis. Ann Rheum Dis. 2006;65:180.
63. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006;108:2648–2654. [PubMed] 64. Weiner GJ, Bowles JA, Link BK, Allan B, Beuerlein G, Campbell MA, et al. An anti-CD20 monoclonal antribody (mAb) with enhanced affinity for CD16 activates NK cells at a lower concentrations and more effectively than rituximab. Blood. 2005;106:348. [PubMed] 65. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007;233-242 [PubMed]
66. Umana P, Moessner E, Bruenker P, Unsin G, Purntener U, Suter T, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood. 2006;108:229.
67. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Grau R, et al. GA101: A humanized third generation type II CD20 antibody with superior cell death induction and glycoengineered Fc region for enhanced ADCC. American Association of Cancer Research Meeting. 2007;48:4186.
68. Umana P, Moessner E, Bruenker P, Unsin G, Suter T, Grau R, et al. Novel third generation humanized type II CD20 antibody with superior direct cell death induction and glycoengineered Fc region for enhanced ADCC induction. AACR-NCI-EORTC International Congress. 2007;19:56.
69. Umana P, Ekkehard M, Peter B, Gabriele K, Puentener U, Suter T, et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood. 2007;110:2348.
70. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10:588–596. [PubMed]
71. Dalle S, Reslan L, Manquat SB, Herting F, Klein C, Umana P, et al. Compared antitumor activity of GA101 and rituximab against human RL folicular lymphoma xenografts in SCID beige mice. Blood. 2008;112:1585.
72. Friess T, Herting F, Bauer S, Nopora A, van Puijenbroek E, Gerdes C, et al. GA101, a novel therapeutic type II CD20 antibody with outstanding efficacy and clear superiority in subcutaneous non Hodgkin lymphoma xenograft models. American Association of Cancer Research Meeting. 2008;99:3982.
73. Nopora A, Preiss S, Nicolini V, Rommele M, van Puijenbroek E, Freyetg O, et al. Contribution of enhanced ADCC to superior in vivo efficacy of a novel type II humanized, third generation CD20 antibody (GA101) in NHL xenograft models. American Association of Cancer Research Meeting. 2008;99:3991.
74. Klein C, Herting F, Friess T, Gerdes C, Nopora A, Bauer S, et al. GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in non-Hodgkin’s lymphoma xenograft models and superior B cell depletion. P EJS SUPPL. 2008;6:504.
75. Umana P, Moessner E, Grau R, Gerdes C, Nopora A, Schmidt C, et al. GA101, a novel human therapeutic type II CD20 antibody with outstanding anti tumor efficacy in non Hodgkins lymphoma xenograft models and superior B cell depletion. Ann Oncol. 2008:19.
76. de Romeuf C, Dutertre CA, Graff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc gamma RIIIA/CD16. Br J Haematol. 2008;140:635–643. [PubMed]